Radiation Oncology MarketSize, Share & Industry Analysis, 2026-2034By Treatment ModalityBy TechniqueBy Product and Service OfferingBy Cancer TypeBy Treatment IntentBy Fractionation RegimenBy End UserBy Patient Age GroupBy Procurement Model
Full title & scope — all 9 axes with their segments
Radiation Oncology Market Size, Share & Industry Analysis, By Treatment Modality (External Beam Radiation Therapy, Proton Therapy, Carbon Ion Therapy, Brachytherapy, Systemic Radioisotope Therapy, Intraoperative Radiotherapy), By Technique (3D Conformal Radiotherapy, Intensity-Modulated Radiotherapy, Volumetric Modulated Arc Therapy, Image-Guided Radiotherapy, Stereotactic Radiotherapy, Adaptive Radiotherapy), By Product and Service Offering (Treatment Delivery Systems, Treatment Planning Software, Oncology Information Systems, Patient Positioning and Immobilization, Quality Assurance and Dosimetry, Radioisotopes and Sealed Sources, Installation, Maintenance and Upgrade Services), By Cancer Type (Prostate Cancer, Breast Cancer, Lung Cancer, Head and Neck Cancer, Colorectal Cancer, Brain and Central Nervous System Tumors, Gynecological Cancer, Other Cancers), By Treatment Intent (Curative, Adjuvant, Neoadjuvant, Palliative), By Fractionation Regimen (Conventional Fractionation, Moderate Hypofractionation, Ultra-Hypofractionation, Hyperfractionation, Accelerated Fractionation), By End User (Hospitals, Independent Radiotherapy Centers, Cancer Research Institutes, Ambulatory Oncology Clinics), By Patient Age Group (Pediatric, Adult, Geriatric), By Procurement Model (Outright Purchase, Leasing and Equipment-as-a-Service, Per-Procedure or Managed Service Contracts, Public Tender and Government Procurement), and Regional Forecast, 2026-2034
Market outlook, key takeaways, drivers and challenges for the report period.

- 01By Treatment ModalityExternal Beam Radiation Therapy · Proton Therapy · Carbon Ion Therapy
- 02By Technique3D Conformal Radiotherapy · Intensity-Modulated Radiotherapy · Volumetric Modulated Arc Therapy
- 03By Product and Service OfferingTreatment Delivery Systems · Treatment Planning Software · Oncology Information Systems
- 04By Cancer TypeProstate Cancer · Breast Cancer · Lung Cancer
- 05By Treatment IntentCurative · Adjuvant · Neoadjuvant
- 06By Fractionation RegimenConventional Fractionation · Moderate Hypofractionation · Ultra-Hypofractionation
- 07By End UserHospitals · Independent Radiotherapy Centers · Cancer Research Institutes
- 08By Patient Age GroupPediatric · Adult · Geriatric
- 09By Procurement ModelOutright Purchase · Leasing and Equipment-as-a-Service · Per-Procedure or Managed Service Contracts
- 10By Region
Market Analysis & Outlook
Radiation oncology covers the equipment, software, isotopes and services used to treat cancer with ionising radiation, whether delivered from outside the body, placed inside it, or given as a radioactive drug. It spans linear accelerators, particle therapy systems, brachytherapy sources, treatment planning and information systems, patient positioning and quality assurance tools, and the service contracts that keep them running. Buyers are hospitals, independent radiotherapy centers, cancer research institutes and ambulatory oncology clinics, with public tenders and leasing providers shaping many purchases.
Between 2025 and 2034 the global radiation oncology market moves from USD 9.8 billion to USD 18.7 billion, compounding at 7.48% a year. Fifteen years are covered in all, taking in USD 7.3 billion in 2020, USD 9.3 billion in 2024, USD 10.5 billion in 2026 and USD 14.01 billion in 2030.
The treatment modality mix shifts over the period. External Beam Radiation Therapy is the largest line in 2025 at USD 7.056 billion, a 72% share, moving to USD 11.594 billion and 62% by 2034. Carbon Ion Therapy grows fastest at 13.58%, taking its share from 1.5% to 2.5%, while Brachytherapy grows slowest at 5.31%. Share moves toward Proton Therapy, Carbon Ion Therapy and Systemic Radioisotope Therapy and away from External Beam Radiation Therapy, Brachytherapy and Intraoperative Radiotherapy, though no line shrinks in revenue terms.
Cut by technique, the largest line is Intensity-Modulated Radiotherapy: 24% of 2025 revenue, worth USD 2.352 billion, and 17% at USD 3.179 billion by 2034. Adaptive Radiotherapy grows faster at 19.48% against 3.41%, moving from 5% of revenue to 13% by 2034. Both this axis and the treatment modality one divide the same revenue, so they are two views of one total, not parts to be added.
Geographically, 41% of 2025 revenue sits in North America (USD 4.018 billion rising to USD 6.732 billion) ahead of Europe at 26% and USD 2.548 billion. Middle East and Africa is smallest, at 4.5%. Share shifts toward Asia Pacific, Latin America and Middle East and Africa over the forecast period, so the regional split repays a close reading.
Behind these figures sit five regions, six treatment modality lines and nine segmentation axes, each reported for every year from 2020 to 2034. The headline 2025 value is arrived at by triangulating published aggregates against category proxies, not by an independent count, and the same applies to the segment, regional and country breakdowns drawn from it.
Market Size, 2020–2034
USD BillionRevenue in USD Billion. Values up to 2025 are actuals; 2026–2034 are forecast.
Key Takeaways
- The global radiation oncology market moves from USD 7.3 billion in 2020 to USD 9.8 billion in 2025 and USD 18.7 billion by 2034, the forecast period compounding at 7.48% a year.
- 72% of 2025 revenue sits in External Beam Radiation Therapy (USD 7.056 billion) and it remains the largest treatment modality line in 2034 at USD 11.594 billion and 62%.
- Fastest growth on the treatment modality axis belongs to Carbon Ion Therapy: 13.58% a year, USD 0.147 billion to USD 0.468 billion, and a share moving from 1.5% to 2.5%.
- Scenario range for 2034 runs from USD 16.1 billion in the bear case to USD 20.9 billion in the bull case, against a base-case USD 18.7 billion, the spread a plan built on this forecast has to absorb.
- 41% of 2025 revenue is generated in North America, worth USD 4.018 billion and rising to USD 6.732 billion by 2034; Middle East and Africa is smallest at 4.5%.
- 89.6% of North America's base-year revenue comes from the United States alone: USD 3.6 billion in 2025, rising to USD 6 billion by 2034, which is why it is that region's worked example.
- The study covers 2020 through 2034 with 2025 as the base year, reporting five regions and nine segmentation axes separately, with revenue, share and a growth rate for every line in each year.
Market Trends
Revenue Share, By treatment modality
Base year 2025External Beam Radiation Therapy leads with 72.0% of treatment modality segment revenue.
Share of treatment modality segment revenue, most recent base year.
Read across the forecast period, the global radiation oncology market shows movement in three places: treatment modality composition, regional weight, and the 7.48% rate applied to the whole.
None of them reverses the market's direction. Every line and every region grows in absolute terms across the period; the movement is in which of them captures the revenue added.
Composition shifts on the treatment modality axis. Between 2026 and 2034, 13.58% growth in Carbon Ion Therapy against 5.31% in Brachytherapy pulls the treatment modality mix apart. Carbon Ion Therapy takes its share of revenue from 1.5% to 2.5% while Brachytherapy gives up ground, from 6% to 5%. In absolute terms Carbon Ion Therapy rises from USD 0.147 billion to USD 0.468 billion, while Brachytherapy rises from USD 0.588 billion to USD 0.935 billion. Both grow; the gap is wide enough to reshape the mix inside a single forecast window.
Asia Pacific, Latin America and Middle East and Africa gain regional share. Asia Pacific moves from 24% of revenue in 2025 to 31% in 2034, worth USD 2.352 billion rising to USD 5.797 billion; Latin America moves from 4.5% of revenue in 2025 to 4.8% in 2034, worth USD 0.441 billion rising to USD 0.898 billion; Middle East and Africa moves from 4.5% of revenue in 2025 to 4.7% in 2034, worth USD 0.441 billion rising to USD 0.879 billion. Share moves off the others in turn: North America at 41% moving to 36%, Europe at 26% moving to 23.5%, each still growing in revenue terms. That makes the regional split worth reading directly instead of scaling from the global rate: the same market rate produces different outcomes depending on where a supplier's revenue sits.
A continuation, not an inflection. Year by year the total runs USD 7.3 billion in 2020, USD 9.3 billion in 2024, USD 9.8 billion in 2025, USD 10.5 billion in 2026, USD 14.01 billion in 2030 and USD 18.7 billion in 2034. Against 6.07% through the historical period, the 7.48% forecast rate is a continuation; no year in the series interrupts it. For a participant that makes planning a question of capturing a share of steady expansion instead of timing a discontinuity, and it is why the treatment modality and regional mixes matter more to a forecast than the headline rate does.
Market Growth Factors
Carbon Ion Therapy adds the most incremental growth
Market Drivers
3- 01Carbon Ion Therapy adds the most incremental growth
Carbon Ion Therapy compounds at 13.58% against 7.48% for the market, rising from USD 0.147 billion in 2025 to USD 0.468 billion in 2034 and from 1.5% of revenue to 2.5%. Set against 5.31% at the other end of the axis, this is the line that decides whether the market's 7.48% holds. A portfolio weighted away from it tracks below the market even in a market growing everywhere.
- 02Growth lands where the revenue already is
North America is the largest region at USD 4.018 billion in 2025, 41% of global revenue, and reaches USD 6.732 billion by 2034 while holding 36%. Europe is next at 26% of revenue, USD 2.548 billion in 2025 and USD 4.395 billion in 2034. Most of the base and most of the growth sit in those two, and a plan spread evenly across regions therefore over-invests outside them.
- 03The base has grown every year since 2020
The historical period compounded at 6.07%; USD 7.3 billion in 2020, USD 9.3 billion in 2024 and USD 9.8 billion in 2025. The forecast period then runs at 7.48%, ending 2034 at USD 18.7 billion. A forecast extending an observed trend is a different proposition from one proposing a turn, and that is why no ramp is applied: the 7.48% runs evenly across the period.
Growth drivers
| # | Growth driver | Impact | Gross contribution (USD Billion) | 2026-28 | 2029-31 | 2032-34 |
|---|---|---|---|---|---|---|
| 1 | Rising cancer incidence and ageing populations | High | +3.6 | High | High | Medium |
| 2 | Shift to hypofractionation and stereotactic treatment | Medium-High | +2.4 | High | High | Medium |
| 3 | Proton and heavy-ion capacity build-out | Medium-High | +2.3 | Medium | High | High |
| 4 | Adaptive planning, automated contouring and software | Medium | +1.9 | Medium | High | High |
| 5 | Others | Low | +1.4 | Medium | Medium | Medium |
| Total | +11.6 | |||||
Restraints
| # | Restraint | Impact | Estimated reduction (USD Billion) | 2026-28 | 2029-31 | 2032-34 |
|---|---|---|---|---|---|---|
| 1 | High capital cost and reimbursement pressure | Medium-High | −1.5 | High | High | Medium |
| 2 | Shortage of radiation therapists and medical physicists | Medium | −0.7 | Medium | Medium | Medium |
| 3 | Radioisotope supply constraints | Medium | −0.5 | Medium | Medium | Low |
| Total | −2.7 | |||||
Drivers contribute 11.6 USD Billion and restraints remove 2.7 USD Billion, a net 8.9 USD Billion, which is the revenue the market adds between the base year and 2034. Contributions are CDI estimates, apportioned so that they reconcile with the forecast rather than being read from it.
Separate the 7.48% into its parts and three show up: an already-large base compounding, the treatment modality mix moving toward its faster lines, and regional growth landing unevenly.
Restraining Factors
The bear case and what drives it
Market Restraints
2- 01The bear case and what drives it
Where the forecast could miss: delayed capital budgets and proton financing, slower radioligand scale-up because of isotope supply limits, and reimbursement cuts that lower revenue per course. That path reaches USD 16.1 billion by 2034 instead of USD 18.7 billion, off an unchanged USD 9.8 billion in 2025.
- 02External Beam Radiation Therapy holds the blended rate down
With 72% of 2025 revenue (USD 7.056 billion) External Beam Radiation Therapy is where most of the market sits, and it grows at only 5.7% against the market's 7.48%. Revenue still reaches USD 11.594 billion by 2034 and share still falls to 62%: a drag on the average, not a decline.
Market Opportunities
Where the forecast could be beaten
Market Opportunities
2- 01Where the forecast could be beaten
What would beat the forecast: faster uptake of adaptive and radioligand therapy, earlier financing of proton projects, and reimbursement that supports shorter courses without cutting per-course payment. That case reaches USD 20.9 billion in 2034 against USD 18.7 billion, and it is worth testing against a reader's own read of the market.
- 02Carbon Ion Therapy is where share changes hands
Share on the treatment modality axis moves toward Carbon Ion Therapy, from 1.5% in 2025 to 2.5% in 2034, on 13.58% growth against the market's 7.48% and revenue rising from USD 0.147 billion to USD 0.468 billion. Taking position there does not require displacing whoever holds External Beam Radiation Therapy, which is the harder and more expensive fight.
Market Challenges
The total depends on a single line
Market Challenges
2- 01The total depends on a single line
USD 7.056 billion of 2025 revenue sits in External Beam Radiation Therapy, 72% of the total, and it is still 62% at USD 11.594 billion nine years later. That concentration means the market's own forecast is, to a large extent, a forecast for one treatment modality line.
- 02One country drives the leading region
North America is worth USD 4.018 billion in 2025 and USD 3.6 billion of that is the United States; 89.6% of the region, reaching USD 6 billion in 2034. Regional totals therefore move largely with one country's demand, so a regional forecast is more exposed to single-country conditions than its size alone suggests.
Segmentation Analysis
9 axesnine segmentation axes are reported; by treatment modality, by technique, product and service offering, cancer type, treatment intent, fractionation regimen, end user, patient age group and procurement model. Every one of them divides the same revenue, which makes them views of one market from different commercial angles, not components of it.
All six treatment modality lines expand in revenue terms over the forecast period. Share is the dividing line; three take it, the others cede it.
By Treatment Modality · 6 segments
Scale in External Beam Radiation Therapy and Growth in Carbon Ion Therapy Define the Treatment modality Axis
- Largest External Beam Radiation Therapy · 72%
- Fastest Carbon Ion Therapy · 13.6%
- Moves most External Beam Radiation Therapy · -10 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| External Beam Radiation Therapy | $7.06B | 72% | $11.59B | 62%-10 | 5.7% |
| Proton Therapy | $0.83B | 8.5% | $2.24B | 12%+3.5 | 11.6% |
| Carbon Ion Therapy | $0.15B | 1.5% | $0.47B | 2.5%+1 | 13.6% |
| Brachytherapy | $0.59B | 6% | $0.94B | 5%-1 | 5.3% |
| Systemic Radioisotope Therapy | $0.98B | 10% | $3.09B | 16.5%+6.5 | 13.4% |
| Intraoperative Radiotherapy | $0.20B | 2% | $0.37B | 2% | 7.5% |
External beam radiation therapy leads because almost every radiotherapy program rests on linear accelerators, and the installed base in hospitals is large and replaced on regular cycles. Carbon ion therapy grows fastest from a small base as new facilities open in Asia and Europe, with systemic radioisotope therapy close behind as radioligand treatments enter routine care. The order does not change: External Beam Radiation Therapy is still largest in 2034, and what moves is how much it holds. This is the axis the estimation prices in full, year by year, and the one the regional chapters cut against.
By Technique · 6 segments
Intensity-Modulated Radiotherapy Led by Technique in 2025, with Adaptive Radiotherapy Growing Fastest
- Largest Intensity-Modulated Radiotherapy · 24%
- Fastest Adaptive Radiotherapy · 19.5%
- Moves most Adaptive Radiotherapy · +8 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| 3D Conformal Radiotherapy | $1.37B | 14% | $1.31B | 7%-7 | -0.5% |
| Intensity-Modulated Radiotherapy | $2.35B | 24% | $3.18B | 17%-7 | 3.4% |
| Volumetric Modulated Arc Therapy | $2.16B | 22% | $4.11B | 22% | 7.4% |
| Image-Guided Radiotherapy | $1.96B | 20% | $3.55B | 19%-1 | 6.8% |
| Stereotactic Radiotherapy | $1.47B | 15% | $4.11B | 22%+7 | 12.1% |
| Adaptive Radiotherapy | $0.49B | 5% | $2.43B | 13%+8 | 19.5% |
Intensity-modulated radiotherapy leads because it became the standard of care for many tumour sites and runs on most installed accelerators. Adaptive radiotherapy grows fastest because online re-planning, enabled by faster imaging and automated contouring, lets clinics adjust to daily anatomy changes. Older conformal techniques lose ground as modulated and stereotactic delivery replace them. By 2034 the largest line is Volumetric Modulated Arc Therapy and no longer Intensity-Modulated Radiotherapy, the one axis here where the order actually changes.
By Product and Service Offering · 7 segments
By Product and Service Offering
- Largest Treatment Delivery Systems · 38%
- Fastest Radioisotopes and Sealed Sources · 12.4%
- Moves most Radioisotopes and Sealed Sources · +7 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Treatment Delivery Systems | $3.72B | 38% | $6.17B | 33%-5 | 5.8% |
| Treatment Planning Software | $0.69B | 7% | $1.50B | 8%+1 | 9.1% |
| Oncology Information Systems | $0.59B | 6% | $1.12B | 6% | 7.4% |
| Patient Positioning and Immobilization | $0.39B | 4% | $0.56B | 3%-1 | 4.1% |
| Quality Assurance and Dosimetry | $0.49B | 5% | $0.84B | 4.5%-0.5 | 6.2% |
| Radioisotopes and Sealed Sources | $1.37B | 14% | $3.93B | 21%+7 | 12.4% |
| Installation, Maintenance and Upgrade Services | $2.55B | 26% | $4.58B | 24.5%-1.5 | 6.7% |
2025 to 2034 revenue and share by line: Treatment Delivery Systems USD 3.724 billion to USD 6.171 billion (38% to 33%), Installation, Maintenance and Upgrade Services USD 2.548 billion to USD 4.581 billion (26% to 24.5%), Radioisotopes and Sealed Sources USD 1.372 billion to USD 3.927 billion (14% to 21%), Treatment Planning Software USD 0.686 billion to USD 1.496 billion (7% to 8%), Oncology Information Systems USD 0.588 billion to USD 1.122 billion (6% to 6%), Quality Assurance and Dosimetry USD 0.49 billion to USD 0.842 billion (5% to 4.5%), Patient Positioning and Immobilization USD 0.392 billion to USD 0.561 billion (4% to 3%). Scale in Treatment Delivery Systems and Growth in Radioisotopes and Sealed Sources Define the Product and service offering Axis Treatment delivery systems lead because each accelerator or particle system is a high-value purchase that anchors the rest of the department. Radioisotopes and sealed sources grow fastest on the spread of radioligand and brachytherapy sources, while service contracts follow the installed base and grow with it as systems age. Treatment Delivery Systems remains the largest line through 2034, so the axis changes in proportion, not in order.
By Cancer Type · 8 segments
By Cancer Type
- Largest Other Cancers · 21%
- Fastest Brain and Central Nervous System Tumors · 8.9%
- Moves most Breast Cancer · -1.5 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Prostate Cancer | $1.76B | 18% | $3.46B | 18.5%+0.5 | 7.8% |
| Breast Cancer | $1.96B | 20% | $3.46B | 18.5%-1.5 | 6.5% |
| Lung Cancer | $1.67B | 17% | $3.18B | 17% | 7.4% |
| Head and Neck Cancer | $0.78B | 8% | $1.40B | 7.5%-0.5 | 6.7% |
| Colorectal Cancer | $0.59B | 6% | $1.12B | 6% | 7.4% |
| Brain and Central Nervous System Tumors | $0.39B | 4% | $0.84B | 4.5%+0.5 | 8.9% |
| Gynecological Cancer | $0.59B | 6% | $1.03B | 5.5%-0.5 | 6.4% |
| Other Cancers | $2.06B | 21% | $4.21B | 22.5%+1.5 | 8.3% |
2025 to 2034 revenue and share by line: Other Cancers USD 2.058 billion to USD 4.205 billion (21% to 22.5%), Breast Cancer USD 1.96 billion to USD 3.46 billion (20% to 18.5%), Prostate Cancer USD 1.764 billion to USD 3.46 billion (18% to 18.5%), Lung Cancer USD 1.666 billion to USD 3.179 billion (17% to 17%), Head and Neck Cancer USD 0.784 billion to USD 1.403 billion (8% to 7.5%), Colorectal Cancer USD 0.588 billion to USD 1.122 billion (6% to 6%), Gynecological Cancer USD 0.588 billion to USD 1.029 billion (6% to 5.5%), Brain and Central Nervous System Tumors USD 0.392 billion to USD 0.842 billion (4% to 4.5%). Other Cancers Held the Dominant Share of the Cancer type Segment in 2025 The Other Cancers group is the largest line because it pools many tumour sites, while breast and prostate are the biggest single indications by treated volume. Brain and central nervous system tumors grow fastest as stereotactic radiosurgery and proton planning extend treatment to more patients and to repeat courses. Other Cancers remains the largest line through 2034, so the axis changes in proportion, not in order.
By Treatment Intent · 4 segments
Curative Led by Treatment intent in 2025, with Neoadjuvant Growing Fastest
- Largest Curative · 48%
- Fastest Neoadjuvant · 10.1%
- Moves most Neoadjuvant · +2 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Curative | $4.70B | 48% | $8.79B | 47%-1 | 7.2% |
| Adjuvant | $1.96B | 20% | $3.74B | 20% | 7.4% |
| Neoadjuvant | $0.78B | 8% | $1.87B | 10%+2 | 10.1% |
| Palliative | $2.35B | 24% | $4.30B | 23%-1 | 6.9% |
Curative treatment leads because most radiotherapy is delivered with the aim of cure, often alongside surgery or drug therapy. Neoadjuvant use grows fastest as clinicians give radiation before surgery to shrink tumours and preserve organs, particularly in rectal, breast and oesophageal care. The order does not change: Curative is still largest in 2034, and what moves is how much it holds.
By Fractionation Regimen · 5 segments
Ultra-Hypofractionation Outpaces the Axis While Conventional Fractionation Holds the Largest Share
- Largest Conventional Fractionation · 40%
- Fastest Ultra-Hypofractionation · 15.1%
- Moves most Conventional Fractionation · -12 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Conventional Fractionation | $3.92B | 40% | $5.24B | 28%-12 | 3.3% |
| Moderate Hypofractionation | $2.94B | 30% | $6.17B | 33%+3 | 8.6% |
| Ultra-Hypofractionation | $1.37B | 14% | $4.86B | 26%+12 | 15.1% |
| Hyperfractionation | $0.59B | 6% | $0.94B | 5%-1 | 5.3% |
| Accelerated Fractionation | $0.98B | 10% | $1.50B | 8%-2 | 4.8% |
Conventional fractionation leads because long-established protocols and clinician habit keep daily small-dose courses standard in many tumour sites. Ultra-hypofractionation grows fastest because clinical evidence now supports fewer, higher-dose sessions, which free machine time and lower the cost per course for providers and payers. By 2034 the largest line is Moderate Hypofractionation and no longer Conventional Fractionation, the one axis here where the order actually changes.
By End User · 4 segments
Hospitals Held the Dominant Share of the End user Segment in 2025
- Largest Hospitals · 72%
- Fastest Independent Radiotherapy Centers · 10.5%
- Moves most Hospitals · -6 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Hospitals | $7.06B | 72% | $12.34B | 66%-6 | 6.4% |
| Independent Radiotherapy Centers | $1.37B | 14% | $3.37B | 18%+4 | 10.5% |
| Cancer Research Institutes | $0.59B | 6% | $1.12B | 6% | 7.4% |
| Ambulatory Oncology Clinics | $0.78B | 8% | $1.87B | 10%+2 | 10.1% |
Hospitals lead because they hold the multidisciplinary teams, imaging and surgical services that complex cancer care needs, and they own most installed accelerators. Independent radiotherapy centers grow fastest as private operators and joint ventures add capacity in regions where hospital waiting lists are long. By 2034 Hospitals is still ahead, making this a shift in weight, not a change of leader.
By Patient Age Group · 3 segments
Geriatric Both Leads the Patient age group Axis and Grows Fastest on It
- Largest Geriatric · 60%
- Fastest Geriatric · 8.2%
- Moves most Adult · -4 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Pediatric | $0.29B | 3% | $0.56B | 3% | 7.4% |
| Adult | $3.63B | 37% | $6.17B | 33%-4 | 6.1% |
| Geriatric | $5.88B | 60% | $11.97B | 64%+4 | 8.2% |
Geriatric patients form the largest group because cancer incidence rises steeply with age and radiotherapy is often preferred when surgery carries too much risk. The same group grows fastest as populations age across every major region, while pediatric volumes stay small and tied to specialist centers. By 2034 Geriatric is still ahead, making this a shift in weight, not a change of leader.
By Procurement Model · 4 segments
Outright Purchase Led by Procurement model in 2025, with Leasing and Equipment-as-a-Service Growing Fastest
- Largest Outright Purchase · 44%
- Fastest Leasing and Equipment-as-a-Service · 14%
- Moves most Outright Purchase · -8 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Outright Purchase | $4.31B | 44% | $6.73B | 36%-8 | 5.1% |
| Leasing and Equipment-as-a-Service | $0.98B | 10% | $3.18B | 17%+7 | 14% |
| Per-Procedure or Managed Service Contracts | $1.18B | 12% | $3.18B | 17%+5 | 11.7% |
| Public Tender and Government Procurement | $3.33B | 34% | $5.61B | 30%-4 | 6% |
Outright purchase leads because most hospitals and public systems still buy equipment from capital budgets. Leasing and equipment-as-a-service grows fastest as providers spread the cost of accelerators and software upgrades and avoid large up-front outlays, while per-procedure contracts attract smaller centers that lack capital. By 2034 Outright Purchase is still ahead, making this a shift in weight, not a change of leader.
Regional Insights
Regional Revenue Share
Base year 2025
Share of global revenue in the base year.
Only the leading region's share is published outside the report; pins mark the region, not a specific country.
North America Market Analysis
The largest region covered — 5 points of share move elsewhere by 2034, while revenue still grows 1.7×.
- Rank 1 of 5
- 2025 share 41%
- By 2034 36%
- Revenue $4.02B → $6.73B
North America holds 41% of the global radiation oncology market in 2025, worth USD 4.018 billion and reaches USD 6.732 billion by 2034. Among the five regions it ranks first by revenue in both years.
Share settles at 36% in 2034, though revenue still rises throughout; the shift is in the region's weight against faster-growing ones, which is not the same as weakening demand.
External Beam Radiation Therapy leads here as it does globally, at 72% of 2025 revenue, and Carbon Ion Therapy again grows fastest at 13.58%. North America is reported axis by axis and country by country in the full study.
United States
Sets the pace for North America at 89.6% of it, growing 1.7×.
- In region 1 of 2
- Of region 89.6%
- Of global 36.7%
- Revenue $3.60B → $6B
USD 3.6 billion of North America's 2025 revenue is generated in the United States, the region's largest market, reaching USD 6 billion by 2034. Because it is 89.6% of the region in the base year, North America's totals move with this one country instead of a spread of them. Regional revenue of USD 4.018 billion in 2025 and USD 6.732 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.
the United States buys along the same lines as the market globally; External Beam Radiation Therapy first at 72% of 2025 revenue and 62% in 2034, Carbon Ion Therapy fastest at 13.58% on a share moving from 1.5% to 2.5%. With 89.6% of North America concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. The United States carries its own treatment modality breakdown in the full report.
Radiation oncology equipment in the United States falls under the Food and Drug Administration, which regulates linear accelerators, brachytherapy systems, treatment planning software and related accessories as medical devices. Suppliers classify each product by risk and reach the market through premarket notification, De Novo classification or premarket approval, depending on novelty and risk. Manufacturers must follow the quality system regulation, device registration and listing, labelling rules and adverse event reporting. Radiation-emitting electronic products also carry performance standards and reporting duties. Radioactive sources and their handling are licensed separately by the Nuclear Regulatory Commission or the relevant state agreement authority.
Siemens Healthineers AG (Varian Medical Systems, Inc.), Elekta AB, Accuray Incorporated, Ion Beam Applications S.A. (IBA), Hitachi, Ltd., Sumitomo Heavy Industries, Ltd., Mevion Medical Systems, Inc., Brainlab AG, RaySearch Laboratories AB, Mirion Technologies, Inc. (Sun Nuclear), Eckert & Ziegler SE, Novartis AG, Bayer AG, Perspective Therapeutics, Inc., Theragenics Corporation, CIVCO Medical Solutions, Best Medical International, Inc., PTW-Freiburg GmbH, Standard Imaging, Inc., Reflexion Medical, Inc., Our United Corporation, Shinva Medical Instrument Co., Ltd., ProTom International Holding Corp., Leo Cancer Care, Inc., ZAP Surgical Systems, Inc. and iCAD, Inc. are the suppliers covered in the United States. The commercially relevant division is 72% of 2025 revenue in External Beam Radiation Therapy, where the volume is, against 13.58% growth in Carbon Ion Therapy, where share moves. Per-company positioning and share at country level are in the full report only.
Canada
2nd-largest in North America, growing 1.7×.
- In region 2 of 2
- Of region 7.5%
- Of global 3.1%
- Revenue $0.30B → $0.52B
Canada is sized at USD 0.3 billion in 2025, rising to USD 0.52 billion by 2034; 3.06% of global revenue and 7.47% of North America. It is reported separately from the United States across every segmentation axis in the full report.
Europe Market Analysis
The 2nd-largest region covered — 2.5 points of share move elsewhere by 2034, while revenue still grows 1.7×.
- Rank 2 of 5
- 2025 share 26%
- By 2034 23.5%
- Revenue $2.55B → $4.39B
In Europe, 26% of global revenue puts 2025 at USD 2.548 billion with USD 4.395 billion projected for 2034. By revenue it sits second across the study, and the ranking does not change between 2025 and 2034.
Its share moves to 23.5% by 2034, while nothing contracts here; other regions simply grow faster, which shows up as relative weight, not as falling revenue.
The treatment modality split here is the one described for North America, led by External Beam Radiation Therapy. Per-axis and per-country detail for Europe sits in the full report.
Germany
The largest market in Europe, growing 1.7×.
- In region 1 of 3
- Of region 20.4%
- Of global 5.3%
- Revenue $0.52B → $0.86B
20.41% of Europe's base-year revenue comes from Germany; USD 0.52 billion, rising to USD 0.86 billion by 2034. At 20.41% of the region in 2025 it leads, but a majority of Europe's revenue is generated in other markets. Against regional totals of USD 2.548 billion in 2025 and USD 4.395 billion in 2034, it is the country the full report breaks out in detail.
Germany buys the treatment modality lines in the global order, with External Beam Radiation Therapy the largest line and Carbon Ion Therapy gaining share fastest; the country's size in the region is the figure that matters here. Because the country carries 20.41% of Europe, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. Germany carries its own treatment modality breakdown in the full report.
Germany applies the European Union Medical Device Regulation to radiation oncology equipment, so a supplier needs conformity assessment by a notified body and the CE mark before sale. Classification follows risk rules in the regulation, and most therapy systems sit in the higher classes. Technical documentation, a quality management system, post-market surveillance and unique device identification are all required. At national level the Federal Institute for Drugs and Medical Devices oversees vigilance, while state authorities supervise operators. Radiation protection law and its ordinances govern installation, shielding, acceptance testing and the qualification of medical physics staff, and the Medical Device Operator Ordinance covers use and maintenance.
The supplier field in Germany is the one this study tracks globally, led by names such as Siemens Healthineers AG (Varian Medical Systems, Inc.) and Elekta AB, and they compete here on the same treatment modality lines. The commercially relevant division is 72% of 2025 revenue in External Beam Radiation Therapy, where the volume is, against 13.58% growth in Carbon Ion Therapy, where share moves. The commercial size of that position is USD 2.548 billion in 2025, moving to USD 4.395 billion by 2034 across the forecast period.
France
2nd-largest in Europe, growing 1.7×.
- In region 2 of 3
- Of region 14.9%
- Of global 3.9%
- Revenue $0.38B → $0.64B
3.88% of global revenue is generated in France; USD 0.38 billion in 2025, reaching USD 0.64 billion in 2034, and 14.91% of Europe.
United Kingdom
3rd-largest in Europe, growing 1.7×.
- In region 3 of 3
- Of region 14.1%
- Of global 3.7%
- Revenue $0.36B → $0.62B
3.67% of global revenue is generated in the United Kingdom; USD 0.36 billion in 2025, reaching USD 0.62 billion in 2034, and 14.13% of Europe.
Asia Pacific Market Analysis
The 3rd-largest region covered, and the one gaining the most — it picks up 7 points of share by 2034, while revenue still grows 2.5×.
- Rank 3 of 5
- 2025 share 24%
- By 2034 31%
- Revenue $2.35B → $5.80B
24% of the global radiation oncology market sits in Asia Pacific in 2025, worth USD 2.352 billion with USD 5.797 billion projected for 2034. Among the five regions it ranks third by revenue in both years.
31% of global revenue sits here by 2034, up from the 2025 level, so the region grows faster than the market's 7.48% and takes a larger part of the revenue added by 2034 than its 2025 weight implies.
External Beam Radiation Therapy is again the largest treatment modality line in Asia Pacific, as it is everywhere the study reports. Per-axis and per-country detail for Asia Pacific sits in the full report.
China
The largest market in Asia Pacific, growing 2.6×.
- In region 1 of 3
- Of region 34%
- Of global 8.2%
- Revenue $0.80B → $2.10B
USD 0.8 billion of Asia Pacific's 2025 revenue is generated in China, the region's largest market, reaching USD 2.1 billion by 2034. It accounts for 34.01% of regional revenue in the base year, the largest single share without dominating the region outright. Against regional totals of USD 2.352 billion in 2025 and USD 5.797 billion in 2034, it is the country the full report breaks out in detail.
The treatment modality lines rank in China as they do worldwide, with External Beam Radiation Therapy the largest line and Carbon Ion Therapy gaining share fastest, so its contribution to Asia Pacific comes from scale and not from an unusual mix. Since 34.01% of Asia Pacific's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. China carries its own treatment modality breakdown in the full report.
In China, radiation oncology devices are regulated by the National Medical Products Administration, which classifies them by risk. Most therapy equipment, including accelerators and brachytherapy systems, is placed in the highest class and requires registration with clinical evaluation and type testing at designated institutes. Imported products need a local legal agent and must meet mandatory national standards, along with Chinese-language labelling and instructions. Large medical equipment is also subject to configuration planning and licensing controlled by health authorities, which governs which hospitals may install and operate such systems. Radiation safety licensing is administered by environmental and health authorities.
Suppliers in China are the same companies covered above, Siemens Healthineers AG (Varian Medical Systems, Inc.) and Elekta AB included; none of them is specific to this market, so position here follows position on the treatment modality axis. The commercially relevant division is 72% of 2025 revenue in External Beam Radiation Therapy, where the volume is, against 13.58% growth in Carbon Ion Therapy, where share moves. A supplier weighted toward Asia Pacific is competing over a base of USD 2.352 billion in 2025, reaching USD 5.797 billion by 2034 on the trajectory this study models.
Japan
2nd-largest in Asia Pacific, growing 1.6×.
- In region 2 of 3
- Of region 27.2%
- Of global 6.5%
- Revenue $0.64B → $1.05B
Within Asia Pacific, Japan accounts for 27.21% of regional revenue and 6.53% of the global total, worth USD 0.64 billion in 2025 and USD 1.05 billion by 2034.
India
3rd-largest in Asia Pacific, growing 3.5×.
- In region 3 of 3
- Of region 9.8%
- Of global 2.4%
- Revenue $0.23B → $0.80B
India is sized at USD 0.23 billion in 2025, rising to USD 0.8 billion by 2034; 2.35% of global revenue and 9.78% of Asia Pacific. It is reported separately from China across every segmentation axis in the full report.
Latin America Market Analysis
The 4th-largest region covered — it picks up 0.3 points of share by 2034, while revenue still grows 2.0×.
- Rank 4 of 5
- 2025 share 4.5%
- By 2034 4.8%
- Revenue $0.44B → $0.90B
4.5% of the global radiation oncology market sits in Latin America in 2025, worth USD 0.441 billion rising to USD 0.898 billion in 2034. That makes it the fourth-largest region covered, in 2025 and again in 2034.
By 2034 the share has moved up to 4.8%, so the region grows faster than the market's 7.48% and takes a larger part of the revenue added by 2034 than its 2025 weight implies.
Nothing in Latin America's treatment modality mix departs from the global order, so External Beam Radiation Therapy leads here too. Latin America is reported axis by axis and country by country in the full study.
Brazil
The largest market in Latin America, growing 2.0×.
- In region 1 of 2
- Of region 45.4%
- Of global 2%
- Revenue $0.20B → $0.40B
Brazil is the largest market within Latin America, generating USD 0.2 billion in 2025 and projected to reach USD 0.4 billion by 2034. 45.35% of the region in the base year makes it the largest market here without making it the region. Regional revenue of USD 0.441 billion in 2025 and USD 0.898 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.
Nothing about the treatment modality mix sets Brazil apart, with External Beam Radiation Therapy the largest line and Carbon Ion Therapy gaining share fastest exactly as at global level; the regional effect comes from how much of Latin America it holds. Its 45.35% weight in Latin America means those movements carry straight into the regional totals. Revenue by treatment modality for Brazil is reported separately in the full report.
The Brazilian Health Regulatory Agency, known as ANVISA, regulates radiation oncology equipment in Brazil. Devices are classified by risk into four classes, and therapy systems generally fall in the higher ones, requiring product registration before sale. Foreign manufacturers appoint a local registration holder and must obtain a certificate of good manufacturing practices. Electrical medical equipment must also be certified for conformity under the national metrology institute's compulsory certification scheme, which refers to international safety standards. Labelling and instructions for use must be in Portuguese. The National Nuclear Energy Commission licenses radioactive sources and treatment facilities, and sets radiation protection requirements for operators.
Brazil has no supplier set of its own: the companies tracked for the market as a whole, Siemens Healthineers AG (Varian Medical Systems, Inc.) and Elekta AB among them, compete across its treatment modality lines. External Beam Radiation Therapy, at 72% of 2025 revenue, is where the volume sits, and Carbon Ion Therapy, growing at 13.58%, is where position changes hands over the forecast period. The commercial size of that position is USD 0.441 billion in 2025 and USD 0.898 billion by 2034, 4.5% of the global total in the base year.
Mexico
2nd-largest in Latin America, growing 2.0×.
- In region 2 of 2
- Of region 17%
- Of global 0.8%
- Revenue $0.07B → $0.15B
0.77% of global revenue is generated in Mexico; USD 0.075 billion in 2025, reaching USD 0.15 billion in 2034, and 17.01% of Latin America.
Middle East and Africa Market Analysis
The 5th-largest region covered — it picks up 0.2 points of share by 2034, while revenue still grows 2.0×.
- Rank 5 of 5
- 2025 share 4.5%
- By 2034 4.7%
- Revenue $0.44B → $0.88B
In Middle East and Africa, 4.5% of global revenue puts 2025 at USD 0.441 billion rising to USD 0.879 billion in 2034. It is a marginal region on this axis, fifth by revenue throughout the period.
4.7% of global revenue sits here by 2034, up from the 2025 level, so the region grows faster than the market's 7.48% and takes a larger part of the revenue added by 2034 than its 2025 weight implies.
Buyers in Middle East and Africa take the same treatment modality lines in the same order as the market overall, with External Beam Radiation Therapy the largest. Revenue for Middle East and Africa is broken out by every segmentation axis and by country in the full report.
Saudi Arabia
The largest market in Middle East and Africa, growing 2.2×.
- In region 1 of 2
- Of region 19.3%
- Of global 0.9%
- Revenue $0.09B → $0.19B
USD 0.085 billion of Middle East and Africa's 2025 revenue is generated in Saudi Arabia, the region's largest market, reaching USD 0.19 billion by 2034. It accounts for 19.27% of regional revenue in the base year, the largest single share without dominating the region outright. Set against USD 0.441 billion and USD 0.879 billion for the region, it is why this market, and not a smaller one, is the one reported in full.
Demand in Saudi Arabia follows the same treatment modality order as the global market, with External Beam Radiation Therapy the largest line and Carbon Ion Therapy gaining share fastest, so what changes the picture here is the country's weight in Middle East and Africa, not a different mix. Since 19.27% of Middle East and Africa's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. The full report reports Saudi Arabia by treatment modality separately.
The Saudi Food and Drug Authority regulates medical devices in Saudi Arabia, including radiation oncology equipment. Suppliers must hold a marketing authorisation for each device, issued after classification by risk and review of technical documentation, usually supported by approval from a recognised reference regulator. Foreign manufacturers appoint an authorised representative in the Kingdom, and establishments must be licensed. Labelling must include Arabic information, and the authority expects conformity with international standards and post-market vigilance reporting. Separately, the Nuclear and Radiological Regulatory Commission licenses facilities that use ionising radiation and radioactive sources, and sets requirements for shielding, safety and staff qualification.
Saudi Arabia is contested by the same suppliers named for North America, Siemens Healthineers AG (Varian Medical Systems, Inc.) and Elekta AB among them, selling into the treatment modality lines described above, not into a market of its own. Volume sits in External Beam Radiation Therapy at 72% of 2025 revenue; movement sits in Carbon Ion Therapy at 13.58% growth. The commercial size of that position is USD 0.441 billion in 2025, moving to USD 0.879 billion by 2034 across the forecast period.
South Africa
2nd-largest in Middle East and Africa, growing 1.7×.
- In region 2 of 2
- Of region 11.3%
- Of global 0.5%
- Revenue $0.05B → $0.09B
South Africa is sized at USD 0.05 billion in 2025, rising to USD 0.085 billion by 2034; 0.51% of global revenue and 11.34% of Middle East and Africa. It is reported separately from Saudi Arabia across every segmentation axis in the full report.
Download a free sample to see the full data tables and segment-level detail behind this analysis.
Report Coverage
This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by treatment modality, technique, product and service offering, cancer type, treatment intent, fractionation regimen, end user, patient age group, procurement model, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.
Competitive Landscape
Position on the Treatment modality Axis Decides Competitive Standing
The study covers the following suppliers: Siemens Healthineers AG (Varian Medical Systems, Inc.), Elekta AB, Accuray Incorporated, Ion Beam Applications S.A. (IBA), Hitachi, Ltd., Sumitomo Heavy Industries, Ltd., Mevion Medical Systems, Inc., Brainlab AG, RaySearch Laboratories AB, Mirion Technologies, Inc. (Sun Nuclear), Eckert & Ziegler SE, Novartis AG, Bayer AG, Perspective Therapeutics, Inc., Theragenics Corporation, CIVCO Medical Solutions, Best Medical International, Inc., PTW-Freiburg GmbH, Standard Imaging, Inc., Reflexion Medical, Inc., Our United Corporation, Shinva Medical Instrument Co., Ltd., ProTom International Holding Corp., Leo Cancer Care, Inc., ZAP Surgical Systems, Inc. and iCAD, Inc..
The competitive line that matters is the treatment modality one, not the geographic one. The largest block of revenue is External Beam Radiation Therapy: USD 7.056 billion in 2025 at 72% of the total, 62% in 2034. Incumbency there is expensive to challenge. Share moves in Carbon Ion Therapy, growing 13.58% against 5.31% for Brachytherapy. A supplier positioned in one is not automatically positioned in the other, so a field of this size stays viable in a market of USD 9.8 billion.
Suppliers separate on the breadth of the treatment platform, how well delivery, imaging, planning and information software work together, and the quality of service across the installed base. Regulatory clearance history and clinical evidence count in every tender. The largest players hold broad portfolios, global service networks and the balance sheet to finance multi-room projects. Proton and carbon ion suppliers compete on turnkey facility delivery and compact system designs that lower building cost. Smaller and regional firms compete on price, niche software or dosimetry tools and local support, while isotope suppliers compete on supply reliability and manufacturing scale.
The regional picture sets the entry cost: 41% of revenue is in North America and 26% in Europe, so a credible global position requires both, while Middle East and Africa at 4.5% can be served opportunistically.
Company-level profiles, financials, shares and development histories are held in the full report and not in this summary.
List of Key Radiation Oncology Market Companies Profiled
26 companies profiled. Company profiles, including financials, product portfolios and recent developments, are part of the full report.
- Siemens Healthineers AG (Varian Medical Systems, Inc.)(Germany)
- Elekta AB(Sweden)
- Accuray Incorporated(United States)
- Ion Beam Applications S.A. (IBA)(Belgium)
- Hitachi, Ltd.(Japan)
- Sumitomo Heavy Industries, Ltd.(Japan)
- Mevion Medical Systems, Inc.(United States)
- Brainlab AG(Germany)
- RaySearch Laboratories AB(Sweden)
- Mirion Technologies, Inc. (Sun Nuclear)(United States)
- Eckert & Ziegler SE(Germany)
- Novartis AG(Switzerland)
- Bayer AG(Germany)
- Perspective Therapeutics, Inc.(United States)
- Theragenics Corporation(United States)
- CIVCO Medical Solutions(United States)
- Best Medical International, Inc.(United States)
- PTW-Freiburg GmbH(Germany)
- Standard Imaging, Inc.(United States)
- Reflexion Medical, Inc.(United States)
- Our United Corporation(China)
- Shinva Medical Instrument Co., Ltd.(China)
- ProTom International Holding Corp.(United States)
- Leo Cancer Care, Inc.
- ZAP Surgical Systems, Inc.(United States)
- iCAD, Inc.(United States)
Geographic Coverage
Every market below is broken out separately in the report.
North America
3Europe
8Asia Pacific
12Latin America
3Middle East and Africa
4Key Insights
Report Scope
Study parameters & segmentationThis study covers market size and forecasts over the 2020–2034 period, segmentation across 9 axes (Treatment Modality, Technique, Product and Service Offering, Cancer Type, Treatment Intent, Fractionation Regimen, End User, Patient Age Group, Procurement Model), regional analysis for 5 regions and their constituent countries, a competitive landscape profiling 26 key companies, and the research methodology behind every estimate.
Segmentation
9 axes + regionQuestions This Report Answers
6 questionsWhat is the market size and growth rate, globally and by region?
How is the market segmented, and which segments lead?
Which regions and countries are covered, and how do they compare?
What are the key drivers, restraints, opportunities and challenges?
Who are the leading companies operating in this market?
What trends are expected to shape the market through the forecast period?
Frequently Asked Questions
01What is the Radiation Oncology Market projected to reach?
USD 18.7 USD Billion by 2034, CAGR 7.48%
02What years does this report cover?
Study period 2020–2034, base year 2025, historical data 2020-2024, forecast period 2026-2034.
03Which regions are covered?
North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
04Which region accounted for the largest market share?
North America leads with 41% of global revenue through 2034.
05Which segment leads the market?
External Beam Radiation Therapy is the largest line by treatment modality, at 72% of revenue in 2025.
06Who are the key companies profiled?
Siemens Healthineers AG (Varian Medical Systems, Inc.), Elekta AB, Accuray Incorporated, Ion Beam Applications S.A. (IBA), Hitachi, Ltd., Sumitomo Heavy Industries, Ltd., Mevion Medical Systems, Inc., Brainlab AG, RaySearch Laboratories AB, Mirion Technologies, Inc. (Sun Nuclear), Eckert & Ziegler SE, Novartis AG, Bayer AG, Perspective Therapeutics, Inc., Theragenics Corporation, CIVCO Medical Solutions, Best Medical International, Inc., PTW-Freiburg GmbH, Standard Imaging, Inc., Reflexion Medical, Inc., Our United Corporation, Shinva Medical Instrument Co., Ltd., ProTom International Holding Corp., Leo Cancer Care, Inc., ZAP Surgical Systems, Inc., iCAD, Inc.. Full profiles are part of the paid report.
07Can the segmentation be customized?
Yes. Custom data cuts by geography, segment, or competitor set are available on request.
Why choose CDI
Need this report shaped around your question?
The scope isn't fixed. Tell us what your team needs that the standard edition doesn't cover, and an analyst will come back on what can be adjusted and how long it takes, before you commit to anything.
Most licences include 30–60 hours of customization at no extra cost. See what each licence includes
Additional Companies
Add competitors, suppliers or the peer set you benchmark against to the companies already covered.
Deeper Competitive View
Sharpen the landscape work around your own position: product line, channel, or a named shortlist of rivals.
Extra Segment Splits
Break the market down along an axis the standard scope doesn't cut it by, or go a level deeper inside one.
Application Focus
Narrow the analysis to the specific use cases and end users your team actually sells into.
Different Time Frame
Move the base year, or widen the historical and forecast windows the study is built on.
Country-Level Detail
Go below region level into the individual countries that matter to you, rather than the standard geography split.